DFS vs ESPR
DFS (DFS) versus Esperion Therapeutics Inc (ESPR) — a side-by-side from cached financials, not a winner call.
DFS (DFS) common stock.
Esperion Therapeutics Inc (ESPR) is a drug manufacturers - specialty & generic company listed on NASDAQ.
DFS does not have a complete income-statement cache yet.
Latest reported ESPR revenue for 2024-12-31 was $332.3M. Net income was -$51.7M. Revenue was up 185.7% from 2023-12-31 to 2024-12-31. ESPR currently screens at market cap $816.9M.
ESPR currently screens at market cap $816.9M.
Not investment advice. Open the DFS and ESPR stock pages for the full models.
Not investment advice.